Form 6-K GENETIC TECHNOLOGIES For: Oct 03
FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
dated October 3, 2016
Commission File Number 0-51504
GENETIC TECHNOLOGIES LIMITED
(Exact Name as Specified in its Charter)
N/A
(Translation of Registrants Name)
60-66 Hanover Street
Fitzroy
Victoria 3065 Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x |
Form 40-F o |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o |
No x |
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: October 3, 2016
|
GENETIC TECHNOLOGIES LIMITED | ||
|
| ||
|
| ||
|
By: |
/s/ Kevin Fischer | |
|
|
Name: |
Kevin Fischer |
|
|
Title: |
Company Secretary |
Exhibit 99.1
ASX ANNOUNCEMENT
3 October 2016
Genetic Technologies Launches BREVAGenplus® Marketing Program
Around Susan G. Komen®s Race for the Cure® Events
Melbourne, Australia, 3 October 2016: Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE; Company) announced today that it will be conducting a promotional campaign around the Susan G. Komen Race for the Cure events. This program will commence at the Susan G. Komen Dallas Race for the Cure in Dallas, on October 15 2016, which coincides with National Breast Cancer Awareness Month. Two contests will anchor the initiative and will feature, in person, BREVAGenplus spokesperson and Susan G. Komen advocate, Verizon IndyCar series driver, Pippa Mann.
We are pleased to join Susan G. Komen in the worlds largest fundraising initiative to fight breast cancer, commented Mr. Eutillio Buccilli, Chief Executive Officer of Genetic Technologies Limited. By participating at these Race for the Cure events we reaffirm our commitment to supporting the important work Komen does on behalf of the breast cancer community. We are pleased to have Pippa on site in Dallas for this Race to help us raise awareness of the importance risk assessment plays in the prevention and early detection of the disease.
Participants who visit the BREVAGenplus booth, which will be located in the Sponsor Expo Area, south of the Main Stage, will be encouraged to fill out the BREVAGenplus Quiz at that time, and will be entered to win an iPad mini. Pippa will be present at the booth to greet participants and to discuss the threat represented by breast cancer and the importance of risk assessment, especially for women with little to no family history. Breast cancer will affect 1 in 8 women during their lifetime. In parallel, the Company will be conducting a social media contest whereby the first 100 participants will receive a signed Pippa Mann poster. In order to enter the contest, participants need to re-tweet or share one of BREVAGenplus social media posts or use the hashtag #KnowYourRisk.
About Genetic Technologies Limited
Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage womens health. The Companys lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus® improves upon the predictive power of the first generation BREVAGen test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGenplus® expands the application of BREVAGen from Caucasian women to include African-Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer.
The Company has successfully launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. and the addition of BREVAGenplus®, launched in October 2014,
Genetic Technologies Limited · Website: www.gtglabs.com · Email: [email protected] ABN 17 009 212 328
Registered Office · 60-66 Hanover Street Fitzroy Victoria 3065 Australia · Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia
Phone +61 3 8412 7000 · Fax +61 3 8412 7040
significantly expands the applicable market. The Company markets BREVAGenplus® to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons).
For more information, please visit www.brevagenplus.com and www.phenogensciences.com.
About Susan G. Komen® and Susan G. Komen® Dallas County
Susan G. Komen is the worlds largest breast cancer organization, funding more breast cancer research than any other nonprofit outside of the federal government while providing real-time help to those facing the disease. Komen was founded in 1982 by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzys life. Komen Dallas County is working to better the lives of those facing breast cancer in the local community. Through events like the Komen Dallas Race for the Cure, Komen Dallas County has invested over $24 million in community breast health programs in Dallas County and has contributed to the more than $920 million invested globally in research. For more information about Komen Dallas County, call 214-750-7223 or visit www.komen-dallas.org.
Safe Harbor Statement
Any statements in this press release that relate to the Companys expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Companys actual results may differ materially from expected results. Additional risks associated with Genetic Technologies business can be found in its periodic filings with the SEC.
FOR FURTHER INFORMATION PLEASE CONTACT
Mr. Eutillio Buccilli |
|
Candice Knoll (USA) |
Executive Director & Chief Executive Officer |
|
Blueprint Life Science Group |
Genetic Technologies Limited |
|
+ 1 (415) 375 3340, Ext. 4 |
+61 3 8412 7050 |
|
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
- Genetic Technologies Announces $2 Million Registered Direct Offering
- Down Payment Resource reports highest annual down payment assistance program count growth on record
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!